linifanib (ABT-869)

News alerts, weekly reports and conference planners

Company:

AbbVie

Drug class:

c-KIT inhibitor, VEGFR inhibitor, PDGFR inhibitor, FLT3 inhibitor

RNASET2 overexpression	Clear Cell Renal Cell Carcinoma	RNASET2 overexpression	Clear Cell Renal Cell Carcinoma	ABT-869 Sensitive: C3 – Early Trials ABT-869 Sensitive : C3	ABT-869 Sensitive: C3 – Early Trials ABT-869 Sensitive : C3
BBOX1 underexpression	Renal Cell Carcinoma	BBOX1 underexpression	Renal Cell Carcinoma	ABT-869 Sensitive: D – Preclinical ABT-869 Sensitive : D	ABT-869 Sensitive: D – Preclinical ABT-869 Sensitive : D

Associations
(2)